BeOne Medicines Ltd. (ONC) operating KPIs
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302313% above fair value
$370.33−1.23 (-0.33%)
Close on Oct 30, 2026Market cap $42.11BP/E 66.2Yield –
BeOne Medicines payments & Credits Applied Against Sales Rebates & Returns Reserve ($M) ($M)
Form 10-Q / 10-K Accrued Sales Rebates Rollforward Note (XBRL)
Latest, Q2 2026
479
Period ended Jun 30, 2026
Change on a year earlier
+59.4%
301 in Q2 2025
History
34 quarters
Since Q1 2018
Sources
29
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Payments & Credits Applied Against Sales Rebates & Returns Reserve ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 479 | +59.4% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2026 | Mar 31, 2026 | 382 | +35.0% | Form 10-Q (filed 2026-05-06) ↗ |
| Q4 2025 | Dec 31, 2025 | 382 | +39.4% | Form 10-K (filed 2026-02-26) ↗ |
| Q3 2025 | Sep 30, 2025 | 292 | +33.5% | Form 10-Q (filed 2025-11-06) ↗ |
| Q2 2025 | Jun 30, 2025 | 301 | +22.5% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2025 | Mar 31, 2025 | 283 | +84.9% | Form 10-Q (filed 2026-05-06) ↗ |
| Q4 2024 | Dec 31, 2024 | 274 | +110.1% | Form 10-K (filed 2026-02-26) ↗ |
| Q3 2024 | Sep 30, 2024 | 219 | +99.6% | Form 10-Q (filed 2025-11-06) ↗ |
| Q2 2024 | Jun 30, 2024 | 245 | +45.1% | Form 10-Q (filed 2025-08-06) ↗ |
| Q1 2024 | Mar 31, 2024 | 153 | +145.0% | Form 10-Q (filed 2025-05-07) ↗ |
| Q4 2023 | Dec 31, 2023 | 131 | +84.3% | Form 10-K (filed 2025-02-27) ↗ |
| Q3 2023 | Sep 30, 2023 | 110 | +55.5% | Form 10-Q (filed 2024-11-12) ↗ |
| Q2 2023 | Jun 30, 2023 | 169 | +180.4% | Form 10-Q (filed 2023-08-02) ↗ |
| Q1 2023 | Mar 31, 2023 | 62.4 | +230.2% | Form 10-Q (filed 2024-05-08) ↗ |
| Q4 2022 | Dec 31, 2022 | 70.8 | +378.4% | Form 10-K (filed 2024-02-26) ↗ |
| Q3 2022 | Sep 30, 2022 | 70.5 | +273.0% | Form 10-Q (filed 2023-11-09) ↗ |
| Q2 2022 | Jun 30, 2022 | 60.3 | +102.3% | Form 10-Q (filed 2023-08-02) ↗ |
| Q1 2022 | Mar 31, 2022 | 18.9 | +425.0% | Form 10-Q (filed 2023-05-04) ↗ |
| Q4 2021 | Dec 31, 2021 | 14.8 | +270.0% | Form 10-K (filed 2023-02-27) ↗ |
| Q3 2021 | Sep 30, 2021 | 18.9 | +3,050.0% | Form 10-Q (filed 2022-11-09) ↗ |
| Q2 2021 | Jun 30, 2021 | 29.8 | +1,254.5% | Form 10-Q (filed 2022-08-08) ↗ |
| Q1 2021 | Mar 31, 2021 | 3.60 | +1,100.0% | Form 10-Q (filed 2022-05-09) ↗ |
| Q4 2020 | Dec 31, 2020 | 4 | +48.1% | Form 10-K (filed 2022-02-28) ↗ |
| Q3 2020 | Sep 30, 2020 | 0.60 | -50.0% | Form 10-Q (filed 2021-11-04) ↗ |
| Q2 2020 | Jun 30, 2020 | 2.20 | +69.2% | Form 10-Q (filed 2021-08-05) ↗ |
| Q1 2020 | Mar 31, 2020 | 0.30 | -88.0% | Form 10-Q (filed 2021-05-06) ↗ |
| Q4 2019 | Dec 31, 2019 | 2.70 | +3.8% | Form 10-K (filed 2021-02-25) ↗ |
| Q3 2019 | Sep 30, 2019 | 1.20 | – | Form 10-Q (filed 2020-11-05) ↗ |
| Q2 2019 | Jun 30, 2019 | 1.30 | -65.8% | Form 10-Q (filed 2020-08-06) ↗ |
| Q1 2019 | Mar 31, 2019 | 2.50 | – | Form 10-Q (filed 2019-05-09) ↗ |
| Q4 2018 | Dec 31, 2018 | 2.60 | – | Form 10-K (filed 2020-03-02) ↗ |
| Q3 2018 | Sep 30, 2018 | 0 | – | Form 10-Q (filed 2018-11-08) ↗ |
| Q2 2018 | Jun 30, 2018 | 3.80 | – | Form 10-Q (filed 2018-08-09) ↗ |
| Q1 2018 | Mar 31, 2018 | 0 | – | Form 10-Q (filed 2018-05-09) ↗ |
Cite this data
StockData. (2026). BeOne Medicines Payments & Credits Applied Against Sales Rebates & Returns Reserve ($M) ($M), quarterly Q1 2018–Q2 2026 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/gtn_payments
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.